argenx to Host Virtual R&D Day on July 20, 2021
14 Luglio 2021 - 07:00AM
July 14, 2021Breda, the
Netherlands – argenx (Euronext & Nasdaq: ARGX), a
global immunology company committed to improving the lives of
people suffering from severe autoimmune diseases and cancer, today
announced that it will host a virtual R&D Day on Tuesday, July
20, 2021 at 3:00 p.m. CET (9:00 a.m. ET) to highlight its ‘argenx
2025 vision’ and provide an update of its immunology pipeline. The
event will introduce the fifth and sixth indications for the
Company’s FcRn antagonist, efgartigimod, and will include Phase 1
data from its C2 inhibitor, ARGX-117.
In addition to argenx management presentations,
the live event will include a moderated panel discussion on the
treatment paradigm and clinical unmet needs of the new efgartigimod
indications, featuring:
- Rohit Aggarwal, M.D., M.S., Rheumatology, Professor of
Medicine, Medical Director, Arthritis and Autoimmunity Center,
Co-Director UPMC Myositis Center, Division of Rheumatology and
Clinical Immunology, Department of Medicine, University of
Pittsburgh
- Russell P. Hall III, M.D., J. Lamar Callaway Professor,
Department of Dermatology, Duke University Medical Center
To complement the live event, the Company is hosting a program
microsite with additional resources, including:
- Disease overview presentations from Dr. Aggarwal and Dr.
Hall
- Moderated panel on the role of albumin in patients with
autoimmune disease, featuring:
- John Kastelein, M.D., Ph.D., FESC, Emeritus Professor of
Medicine at the Department of Vascular Medicine at the Academic
Medical Center of the University of Amsterdam
- Daniel Rader, M.D., Seymour Gray Professor of Molecular
Medicine at the Perelman School of Medicine at the University of
Pennsylvania
- Current overview of myasthenia gravis in China, featuring:
- Chongbo Zhao, M.D., Ph.D., Professor and Chief Physician,
Department of Neurology, Huashan Hospital, Fudan University
- Patient stories
- Relevant publications
Access to the microsite, including the live
webcast of the virtual event, can be found on the Investors section
of the argenx website at argenx.com/investors. A replay of the
event will be available on the argenx website for approximately one
year following the call.
Dial-in numbers:Please dial in
15 minutes prior to the live call.
Belgium
0800
389 13France
0805
102
319Netherlands 0800
949 4506United Kingdom
0800 279 9489United
States 1 844 808 7140
International
1 412 902 0128
About argenx
argenx is a global immunology company committed to improving the
lives of people suffering from severe autoimmune diseases and
cancer. Partnering with leading academic researchers through its
Immunology Innovation Program (IIP), argenx aims to translate
immunology breakthroughs into a world-class portfolio of novel
antibody-based medicines. argenx is evaluating efgartigimod in
multiple serious autoimmune diseases. argenx is also advancing
several earlier stage experimental medicines within its therapeutic
franchises. argenx has offices in Belgium, the United States,
Japan, and Switzerland. For more information, visit www.argenx.com
and follow us on LinkedIn at
https://www.linkedin.com/company/argenx/ and Twitter at
https://twitter.com/argenxglobal.
For further information, please contact:
Media:Kelsey Kirkkkirk@argenx.com
Joke Comijn jcomijn@argenx.com
Investors:
Beth DelGiaccobdelgiacco@argenx.com
Michelle Greenblattmgreenblatt@argenx.com
Grafico Azioni Argen X (EU:ARGX)
Storico
Da Feb 2024 a Mar 2024
Grafico Azioni Argen X (EU:ARGX)
Storico
Da Mar 2023 a Mar 2024